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The P64k protein of Neisseria meningitidis has been reported as an immunological carrier for weak immunogens. This investi-
gation was aimed at characterizing the T-cell response produced in primed mice and at identifying T helper cell epitopes within this
molecule. BALB/c mice subcutaneously immunized with the recombinant antigen provided inguinal lymph node cells (LNC) that
proliferated in the presence of P64k in a dose-dependent manner. Proliferating cells secreted IL-4 while the concentration of IL-12
remained unaltered in the culture supernatant. By testing a panel of 59 overlapping synthetic peptides spanning the entire sequence
of the antigen a T-cell determinant was localized. Prime-boost and lymphoproliferation experiments, conducted with highly purified
synthetic peptides, confirmed that the segment including amino acids 470–485 comprises a T-cell epitope within the P64k molecule.
 2004 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.
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Mapping of T-cell epitopes and characterization of
cellular response are important for vaccine develop-
ment, understanding of disease pathogenesis, monitor-
ing of disease development and analysis of immune
response in general. Neisseria meningitidis is a pathogen
responsible of a great number of cases of bacterial
meningitis worldwide [1]. Our group has previously
identified and cloned the lpdA gene, which encodes the
P64k protein of N. meningitidis [2]. The P64k protein has
been expressed as a soluble antigen in Escherichia coli,
accounting for more than 20% of the total cell proteins.
Pure recombinant antigen has been extensively charac-
terized [3,4]. The lpdA gene, as well as the P64k protein,* Corresponding author. Tel.: +53-7-271-6221; fax: +53-7-271-4764.
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doi:10.1016/j.femsim.2004.05.007is highly conserved all through the studied strains of
meningococci.
Due to its relatively high molecular weight, demon-
strated immunogenicity [5] and availability, P64k was
employed as a carrier protein for poorly immunogenic
peptides and N. meningitidis serogroup C polysaccharide
with good results [6]. Moreover, the recombinant P64k
acted as a carrier in a novel cancer vaccine, developing a
self-reactive antibody response against human Epider-
mal Growth Factor, in patients with histologically
proven malignant carcinomas [7]. This antibody re-
sponse is desirable during the active immunotherapy
with Epidermal Growth Factor in cancer patients.
B-cell epitopes present in P64k, recognized by
monoclonal and polyclonal antibodies developed in
animals, have been reported [5,8]. Having into account
the prospective use of the recombinant P64k protein as a
carrier in prophylactic, as well as in therapeutic vac-. Published by Elsevier B.V. All rights reserved.
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response against this bacterial protein. This investiga-
tion was aimed at characterizing the T-cell response
produced in primed mice and at identifying T-helper cell
epitopes within this molecule.2. Materials and methods
2.1. Mice
BALB/c (H-2d ) mice were obtained from Centro para
la Produccion de Animales de Laboratorio (CENPA-
LAB), Havana, Cuba, with the exception of mice em-
ployed in the T-cell epitope scanning. Those mice were
supplied by the Center for Genetic Engineering and
Biotechnology of New Delhi, India. All mice (female)
were used at age 6–8 weeks.
2.2. In vitro proliferation assay with P64k
The purified P64k protein employed in this assay
passed the pyrogenicity test, performed in accordance
with the requirements of the United States Pharmaco-
poeia [9]. Mice were subcutaneously immunized at the
base of tail with 20 lg per mouse of recombinant protein
as an emulsion in Complete Freund’s Adjuvant. Seven
days later, three mice were killed, inguinal lymph nodes
were removed, pooled and the cells were dispersed
manually. Once washed and counted, viable cells (LNC)
were cultured at a density of 3–5 105 cells per well in
RPMI 1640 supplemented with 10% fetal calf serum, 2
mM L-glutamine, 50 lgml1 gentamicin and 50 lM 2-
mercaptoethanol, in 96-well Costar plates. Different
concentrations of P64k diluted in the same medium were
added to triplicate wells to give a total volume of 200 ll
per well. Controls were run with complete culture me-
dium or 2.5 lgml1 Concanavalin A, to demonstrate
the proliferative capacity of the cells. Plates were incu-
bated at 37 C in 5% CO2 in air. After three days, cells
were pulsed with 0.5 lCi of [3H]thymidine per well for
an additional 15 h, harvested with an Skatron Auto-
matic Cell Harvester (Skatron, Norway), and counted in
a liquid scintillation counter. Results of proliferative
assays were expressed as stimulation index (SI), i.e., the
ratio of counts per minute in culture with stimulus to
counts per minute in control cultures without stimulus.
At least, three parallel experiments were run, with three
mice per variant, each. An SI >2 was considered
positive.
2.3. Cytokine quantitation
Nine mice were sensitized as described in Section 2.2.
Then, LNC from three mice were obtained, pooled and
cultured as indicated, in the presence of P64k (20, 5 and0.5 lgml1), complemented RPMI 1640 medium or
Concanavalin A. Supernatants of triplicate cell cultures
were collected and pooled 24 and 72 h later for Inter-
leukin-4 (IL-4) and IL-12 measurements. IL-4 and IL-12
concentrations were determined by a capture ELISA
assay using paired monoclonal antibodies specific for
murine IL-4 and IL-12, supplied by R&D Systems,
USA. ELISA assays were done following the manufac-
turer instructions, with recombinant cytokines (pro-
vided with the assay) used for standard curves with the
respective monoclonal antibodies. The experiment was
conducted three times.
2.4. Localization of T-cell epitopes on P64k
Initially, 59 overlapping synthetic peptides that en-
compassed the full-length 596 amino acids of the protein
were synthesized, using the Multipin Cleavable Peptide
Kit (Chiron Technologies, Australia). Peptides were
synthesized as 20-mers, with adjacent peptides overlap-
ping by 10 amino acids. LNC of P64k-sensitized mice
were tested for proliferation in the presence of the
peptides, as described in Section 2.2. In separate ex-
periments, all the peptides were tested in three different
concentrations (30, 10 and 1 lgml1). To perform the
mapping with all the peptides simultaneously, 10
lgml1 was the peptide concentration selected.
Later, synthetic peptides P1 (20-mer), P48 (25-mer),
P48A, P48B and P48C (15-mer, each), derived from the
amino acid sequence of P64k, were synthesized using
Fmoc chemistry on Rink resin. Crude peptides were
purified to at least 95% purity by reverse phase-high
performance liquid chromatography. All the prolifera-
tive response assays with synthetic peptides were per-
formed as described above, employing 50 lg of peptide
or 20 lg of P64k emulsified in Complete Freund’s Ad-
juvant for the sensitization. A non-related peptide (C13),
derived from the sequence of the PorB meningococcal
protein was synthesized using the same approach. This
peptide was employed as a negative control in several
experiments.
2.5. Prime boost immunization experiment
The prime-boost immunization in mice was per-
formed by sensitizing seven mice per group with either
50 lg of peptide or 1 lg of recombinant P64k protein
in Complete Freund’s Adjuvant and boosting the ani-
mals, seven days later, with 1 lg of P64k in Incomplete
Freund’s Adjuvant. Peptide C13 was employed as a
non-related control. Serum samples were taken once a
week during 35 days preserved at )20 C, and tested
for the presence of anti-P64k antibodies by an standard
ELISA test. The plates were coated with P64k (1
lgml1) and the immunoassay continued as described
elsewhere [10].
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A one-way analysis of variance, followed by a Bon-
ferroni’s Multiple Comparison test was used to analyze
the significance of the results obtained in IL-4 and IL-12
quantitation. Data were determined to be significant at
p < 0:05.Fig. 2. IL-4 (a) and IL-12 (b) detected in culture supernatants of
primed LNC stimulated with P64k. Three mice were sensitized with
P64k and LNC were obtained from inguinal lymph nodes. Cells were
stimulated with different concentrations of the same antigen. At the
times indicated in the x axis the supernatants were collected. The
concentrations of IL-4 and IL-12 were determined by ELISA (R&D
Systems). They represent the average of three independent experi-
ments. Numbers in the legend indicate the concentrations of P64k
(lgml1) used to stimulate LNC.3. Results
3.1. Cellular immune response against recombinant P64k
BALB/c mice were subcutaneously immunized with
P64k (20 lg per animal) in Complete Freund’s Adju-
vant. Seven days later, inguinal LNC were tested for
proliferation in the presence of this recombinant anti-
gen, and a dose-dependent lymphoproliferation was
observed (Fig. 1). The assay was performed as well with
LNC obtained on day 14, seven days after the second
dose of recombinant protein. The same pattern of pro-
liferative response was obtained (data not shown).
In the same experimental model, the presence of IL-4
and IL-12 in cell culture supernatants was studied. In
Fig. 2 it can be observed that the level of IL-4 secreted
24 h after the antigenic stimulation was negligible.
However, the amount of this cytokine increased, and
after 72 h of stimulation with P64k (20 lgml1) the
amount of IL-4 was statistically different ðp < 0:05Þ
from the level secreted in the absence of antigen.
Nonetheless, the concentration of IL-12 remained un-
altered in the culture supernatant all over the duration
of the experiment.
3.2. Mapping of T-cell epitopes in P64k
Proliferation of P64k-primed LNC was also observed
when the cells were stimulated with two overlappingFig. 1. P64k-stimulated dose-dependent proliferation (SD) of murine
LNC. BALB/c mice were sensitized with a single injection of P64k in
Complete Freund’s Adjuvant. LNC were obtained from inguinal
lymph nodes of three mice immunized with the recombinant protein.
The results shown are representative of three independent experiments.
SI: Stimulation Index.peptides (peptides 48 and 49) from a library of 59 pep-
tides (20-mers each) spanning the entire sequence of
P64k protein. Fig. 3 shows the results achieved in such
experiments, when the cells were simultaneously stimu-
lated with 10 lgml1 of each peptide.
Starting from this result, two peptides (P1 and P48)
were synthesized and purified to continue with the cel-
lular response experiments. P1 corresponds to the N-
terminal peptide of the library and P48 is five amino
acids longer than the respective peptide 48. Fig. 4 shows
the proliferative response given by LNC when P1 and
P48 were used to sensitize mice. Only LNC obtained
from P48 mice produced a positive proliferative re-
sponse when challenged with the homologous peptide.
The results presented are representative of three inde-
pendent proliferation assays. When these experiments
were carried out in parallel in C57BL/6 mice, neither P1
nor P48 stimulated lymphocyte proliferation (data not
shown).
To confirm the results obtained in vitro, the capacity
of the peptides P1 and P48 of sensitizing mice for an in
vivo secondary response was studied. Fig. 5 shows the
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Fig. 3. Lymphocyte proliferation of P64k-sensitized LNC induced by overlapping peptides. LNC were obtained from inguinal lymph nodes of three
mice immunized with the recombinant protein. Fifty nine peptides spanning the whole sequence of the meningococcal P64k protein were synthesized
and used to stimulate LNC. The peptides were tested at 10 lgml1. The results shown are the average (plus standard deviation) of two independent
experiments. SI: Stimulation Index.
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with either P1 or P48 and boosted, seven days later, with
1 lg of recombinant antigen. P48 sensitized the animals
for an anti-P64k secondary response, while P1 behaved
like the non-related peptide.
Finally, three overlapping peptides (P48A, P48B, and
P48C), spanning the P48 sequence, were tested for
proliferation in homologous peptide-sensitized mice
(Fig. 6). To determine the minimal epitope, these pep-
tides were synthesized as 15-mers, with adjacent peptides
overlapping by 10 amino acids. The highest proliferative
response was obtained against peptide P48A, which in-
cludes amino acids 470–485. When primed LNC were
challenged in vitro with peptide P48 similar results were
observed (data not shown).Fig. 4. Lymphocyte proliferative response of peptide-primed LNC.
BALB/c mice were immunized with 50 lg of peptide P1 or P48
emulsified in Complete Freund’s Adjuvant. Seven days later, LNC
were stimulated with several concentrations of the homologous pep-
tide. The results shown are representative of three independent ex-
periments. SI: Stimulation Index.4. Discussion
The humoral immune response is an essential defense
line against the microorganisms. However, T-cell medi-
ated immunity also plays an important role in protec-
tion against pathogens [11]. The CD4+ helper T-cells
offer help to B-cells in the production of antibodies and
they secrete a series of cytokines that are involved in a
variety of immunoregulatory functions or they have a
direct effect on the invader microorganism [12].
The inguinal LNC of P64k-sensitized mice showed
positive lymphoproliferative response, when challenged
during 96 h with the same antigen. This result was ex-
pected, because it is accepted that CD4+ T-cells are
easily generated after the immunization with soluble0
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Fig. 5. A single dose of peptide P48 primed for a P64k-specific sec-
ondary antibody response. Mice ðn ¼ 7Þ were subcutaneously immu-
nized with 50 lg of peptide (1 lg of P64k in the control group) in
Complete Freund’s Adjuvant. Seven days later, animals were boosted
with 1 lg of P64k in Incomplete Freund’s Adjuvant. P64k-specific
antibodies were determined by ELISA in serum samples obtained at
times indicated in the x axis. In the legend are shown the immunogens
used for priming. The results shown are the average (plus standard
deviation) of individual animals in each group.
Fig. 6. P48A produced a proliferative response as strong as the parent
peptide P48. Three overlapping peptides spanning the sequence of
peptide P48 were synthesized. Mice were sensitized with 50 lg of
peptide emulsified in Complete Freund’s Adjuvant. Seven days later,
LNC were obtained from three mice and were stimulated with ho-
mologous peptide. The results shown are representative of three in-
dependent experiments. SI: Stimulation Index.
S. Gonzalez et al. / FEMS Immunology and Medical Microbiology 42 (2004) 233–239 237antigens [13], which is the case of recombinant P64k
protein.
It is well-known that there are at least two sub-
populations of CD4+ T-cells, based on its functions
and on cytokine secretion [14]. In this study, we found
that murine P64k-primed LNC, stimulated in culture
with the same antigen (20 lgml1), secreted levels of
IL-4 higher than those secreted by unstimulated cells,
while the amount of secreted IL-12 did not differ from
the control. It should be taken into account that mice
were primed with the antigen in Complete Freund’s
Adjuvant, which is one of the most potent adjuvants
described so far [15]. In general, adjuvants modulate
the immune responses by prolonging the antigen pre-
sentation, increasing the expression of MHC I and II,
up-regulating adhesion molecules and augmenting cy-
tokine production [16]. Adjuvants can also modulate
the immune response to different T-helper cells [17]. In
this study, the use of Freund’s Adjuvant might have
influenced in the amount of IL-4 that was detected.
Use of another adjuvant may result in a completely
different pattern of secreted cytokines and a dissimilar
Th1/Th2 ratio. Moreover, it has been suggested that
Freund’s Adjuvant might partly unfold the P64k pro-
tein [18], which could facilitate antigen processing. It
appears that a primary goal of antigen processing is to
unfold the protein to expose residues that are buried in
the native conformation. Berzofsky and co-workers
have found that, although the antigen presenting cell
usually accomplishes this task by proteolytic cleavage
of the protein, artificial unfolding without proteolysis is
sufficient [19].
The production of cytokines exclusive, or almost ex-
clusive, of a particular population of T-cells is a reliable
method for the demonstration of the induction in vivo
of such a population of cells [20]. The secretion of IL-4in this type of assay is considered as an indicative of a
Th2 type of response [21]. The Th2 cells are considered
the true helper T-cells; the cytokines secreted by them
play a key role in the switch of class of immunoglobulin
and in the differentiation of B-cells, in particular for the
production of IgE, IgA and IgG1 antibodies [22]. Due to
the heterogeneity of the cells in in vitro culture, alter-
native methods of monitoring cytokine production, like
flow cytometric analysis of intracellular staining, could
be performed to confirm the type of response (Th1 or
Th2) against P64k elicited in mice.
Identification of antigenic determinants within pro-
tein molecules is of theoretical importance in under-
standing the fundamental interactions involved in
immune responses and of potential practical value in the
design of subunit vaccines and diagnostic reagents [23].
In 1990, the pin synthesis technique of synthesizing and
screening large number of peptides was extended to the
analysis of T-cell determinants [24].
The T-cell response to many whole proteins is fo-
cused on a limited number of possible determinants,
which can be termed immunodominant. In addition,
other ‘‘less dominant’’ determinants, the subdominant
or cryptic epitopes, can be found within it [25]. To
identify T-cell epitopes on P64k, we obtained overlap-
ping peptides that encompass the full length of the
protein and test their reactivities. LNC of mice primed
with the recombinant P64k protein proliferated after
stimulation with two overlapping peptides (peptides 48
and P49), indicating that the minimal T-cell epitope may
be contained in the shared amino acid segment. Using
this method, we found only one T-cell determinant. This
is in agreement with results published by others, since
there are parasitic [26], viral [27] and even meningo-
coccal proteins [28] that possess one or two immuno-
dominant T-cell epitopes, detected when this kind of
determinants was mapped in mice.
The data, obtained when the highly purified P48
peptide was employed to immunize mice and to stimu-
late primed LNC, validated the results achieved with the
Multipin system. The N-terminal segment of P64k
(which includes the P1 peptide) has been frequently
employed, fused to other proteins, to increase the ex-
pression of heterologous antigens in E. coli, resulting in
hybrid molecules [29]. To be included in vaccines, it was
desirable that a T-cell epitope were present in that re-
gion. However, instead of P1, it was P48 which gave
evidences of containing such an epitope in several in-
dependent experiments. Moreover, P48 contains a T-cell
determinant in humans, according to some T-cell epi-
tope prediction methods implemented as World Wide
Web servers. For example, as predicted by using the
softwares ProPred [30], MHC-Thread [31] and SYF-
PEITHI [32], P48 encloses binding motifs for
HLADRB1*0401, HLA DR B1*0426, HLA DR
B1*0101, HLA DR B1*0701 and other alleles.
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be genetically determined, since it induced a strong
lymphocyte proliferative response in primed cells of
BALB/c mice (H-2d ), but there was no response in
primed cells of C57BL/6 mice (H-2b), cultured and
stimulated in parallel. This is in agreement with a
prediction algorithm for I-Ad binding motifs [33]
which predicts one motif within P48 (PGVAYTSPE)
and no binding motif for I-Ab within it. According to
this prediction the amino acids P, A, T and E could
bind in the pockets of I-Ad and failed to bind in the
pockets of I-Ab. The immunogenicity of a given epi-
tope is dependent upon three factors: the generation
of the appropriate fragment, the presence of an MHC
molecule that binds this fragment and the presence of
T-cells capable of recognizing the complex [34]. Most
experiments with mice indicate the lack of an ap-
propriate MHC molecule as the most frequent cause
of unresponsiveness. Indeed, MHC molecules are
highly polymorphic and it has been shown that a
given peptide can bind to only one or few alleles
[35–37].
To further restrict the amino acid segment able of
inducing proliferation in murine LNC, we tested three
overlapping peptides, spanning the sequence of P48. We
found that peptide P48A, encompassing residues 470–
485 of the entire protein, produced a proliferative re-
sponse as strong as the parent peptide, indicating that
this 15 amino acid segment (IPGVAYTSPEVAWVG)
contains a T-cell epitope for BALB/c mice. It is the first
time that the presence of such an epitope is demon-
strated for this meningococcal protein. In addition,
when we looked at the reported B-cell epitopes, deter-
mined for this antigen [5], we observed that this region
comprises also a B-cell determinant.
Based on the results of this study, and on elements
well-established in the literature, we could presume that
meningococcal P64k can be classified as a T-cell de-
pendent antigen, able of stimulating the Th2 subpopu-
lation of immune cells when Complete Freund’s
Adjuvant is employed for the immunization of mice.
The knowledge existing on this protein, at the molecular
level, as well as its safety and immunogenicity demon-
strated in healthy volunteers [38] supports its use not
only in conjugate vaccines, but also in hybrid molecules,
resulting from the genetic manipulation of this antigen
in order to insert in it protective epitopes from foreign
antigens.Acknowledgements
This work was partially supported by the
International Center for Genetic Engineering and
Biotechnology.References
[1] Peltola, H. (1998) Meningococcal vaccines. Current status and
future possibilities. Drugs 55, 347–366.
[2] Guillen, G., Alvarez, A., Silva, R., Morera, V., Gonzalez, S.,
Musacchio, A., Besada, V., Coizeau, E., Caballero, E., Nazabal,
C., Carmenate, T., Gonzalez, L.J., Estrada, R., Tambara, Y.,
Padron, G. and Herrera, L. (1998) Expression in Escherichia coli
of the lpdA gene, protein sequence analysis and immunological
characterization of the P64k protein from Neisseria meningitidis.
Biotechnol. Appl. Biochem. 27, 189–196.
[3] Gomez, R., Madrazo, J., Gonzalez, J., Chinea, G., Musacchio, A.,
Rodriguez, A. and Padron, G. (1999) Functional and structural
characterization of the recombinant P64k protein of Neisseria
meningitidis. Biotecnologia Aplicada 16, 83–87.
[4] Li, I., Pernot, L., Prange, T., Saludjian, P., Schiltz, M., Fourme,
R. and Padron, G. (1997) Molecular structure of the lipoamide
dehydrogenase domain of a surface antigen from Neisseria
meningitidis. J. Mol. Biol. 269, 129–141.
[5] Gonzalez, S., Vi~na, L., Nazabal, C., Chinea, G., Caballero, E. and
Musacchio, A. (2000) B-cell epitope mapping of the Neisseria
meningitidis P64k protein using overlapping peptides. Biotechnol.
Appl. Biochem. 32, 1–8.
[6] Gonzalez, S., Alvarez, A., Caballero, E., Vi~na, L., Guillen, G. and
Silva, R. (2000) P64k meningococcal protein as immunological
carrier for weak immunogens. Scand. J. Immunol. 52, 113–
116.
[7] Gonzalez, G., Crombet, T., Catala, M., Mirabal, V., Hernandez,
J.C., Gonzalez, Y., Marinello, P., Guillen, G. and Lage, A. (1998)
A novel cancer vaccine composed of human recombinant epider-
mal growth factor linked to a carrier protein: Report of a pilot
clinical trial. Ann. Oncol. 9, 1–5.
[8] Nazabal, C., Carmenate, T., Cruz, S., Gonzalez, S., Silva, R.,
Musacchio, A., Delgado, M. and Chinea, G. (2001) Mapping of
monoclonal antibodies specific to P64k: a common antigen of
several isolates of Neisseria meningitidis. Can. J. Microbiol. 47,
158–164.
[9] United States Pharmacopeia-USP XXIV (2000), United States
Pharmacopeia Convention, 24-19 ed.
[10] Exposito, N., Mestre, M., Silva, R., Nazabal, C., Pe~na, M.,
Martinez, N., Font, M. and Guillen, G. (1999) Preformulation
study of the vaccine candidate P64k against Neisseria meningitidis.
Biotechnol. Appl. Biochem. 29, 113–119.
[11] Mills, K.H.G. (1996) Induction and detection of T-cell responses.
In: Vaccine Protocols (Robinson, A., Farrar, G.H. and Wiblin,
C.N., Eds.), pp. 197–222. Humana Press, Totowa, NJ.
[12] Mills, K.H.G. (1989) Recognition of foreign antigen by T cells
and their role in immune protection. Curr. Opinion Infect. Dis. 2,
804–814.
[13] Mills, K.H.G. (1986) Processing of viral antigens and presentation
to class II-restricted T cells. Immunol. Today 7, 260–263.
[14] Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells:
different patterns of lymphokine secretion lead to different
functional properties. Annu. Rev. Immunol. 7, 145–173.
[15] Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben
Efraim, S. and Gupta, C.K. (1993) Adjuvants – a balance between
toxicity and adjuvanticity. Vaccine 11, 293–306.
[16] Schijns, V.E. (2000) Immunological concepts of vaccine adjuvant
activity. Curr. Opin. Immunol. 12, 456–463.
[17] Gupta, R.K. and Siber, G.R. (1995) Adjuvants for human
vaccines – current status, problems and future prospects. Vaccine
13, 1263–1276.
[18] Gonzalez, S., Nazabal, C., Vi~na, L. and Caballero, E. (1998)
Influence of several adjuvants on the immune response against a
recombinant meningococcal high molecular weight antigen. Dev.
Biol. Stand. 92, 269–276.
S. Gonzalez et al. / FEMS Immunology and Medical Microbiology 42 (2004) 233–239 239[19] Berzofsky, J.A., Brett, S.J., Streicher, H.Z. and Takahashi, H.
(1988) Antigen processing for presentation to T lymphocytes:
function, mechanisms, and implications for the T-cell repertoire.
Immunol. Rev. 106, 5–31.
[20] Thorpe, R., Wadhwa, M., Bird, C.R. and Mire-Sluis, A.R. (1992)
Detection and measurement of cytokines. Blood Rev. 6, 133–148.
[21] Swain, S.L., McKenzie, D.T., Weinberg, A.D. and Hancock, W.
(1988) Characterization of T helper 1 and 2 cell subsets in normal
mice. Helper T cells responsible for IL-4 and IL-5 production are
present as precursors that require priming before they develop into
lymphokine-secreting cells. J. Immunol. 141, 3445–3455.
[22] Coffman, R.L., Seymour, B.W., Lebman, D.A., Hiraki, D.D.,
Christiansen, J.A., Shrader, B., Cherwinski, H.M., Savelkoul,
H.F., Finkelman, F.D. and Bond, M.W. (1988) The role of helper
T cell products in mouse B cell differentiation and isotype
regulation. Immunol. Rev. 102, 5–28.
[23] Lamb, J.R., Ivanyi, J., Rees, A.D., Rothbard, J.B., Howland, K.,
Young, R.A. and Young, D.B. (1987) Mapping of T cell epitopes
using recombinant antigens and synthetic peptides. EMBO J. 6,
1245–1249.
[24] Maeji, N.J., Bray, A.M. and Geysen, H.M. (1990) Multi-pin
peptide synthesis strategy for T cell determinant analysis. J.
Immunol. Meth. 134, 23–33.
[25] Deng, H., Fosdick, L. and Sercarz, E. (1993) The involvement of
antigen processing in determinant selection by class II MHC and
its relationship to immunodominance. APMIS 101, 655–662.
[26] Taborda, C.P., Juliano, M.A., Puccia, R., Franco, M. and
Travassos, L.R. (1998) Mapping of the T-cell epitope in the
major 43-kilodalton glycoprotein of Paracoccidioides brasiliensis
which induces a Th-1 response protective against fungal infection
in BALB/c mice. Infect. Immun. 66, 786–793.
[27] Vandebriel, R.J., van der, K.M., Geerse, L., Steerenberg, P.A. and
Krul, M.R. (1995) A helper T-cell epitope of the E7 protein of
human papillomavirus type 16 in BALB/c mice. Virus Res. 37, 13–
22.
[28] Delvig, A.A., Rosenqvist, E., Oftung, F. and Robinson, J.H.
(1997) T-Cell epitope mapping the PorB protein of serogroup B
Neisseria meningitidis in B10 congenic strains of mice. Clin.
Immunol. Immunopathol. 85, 134–142.[29] Duarte, C., Guillen, G., Alvarez, A., Carpio, E., Quintana, D.,
Gomez, C.E., Silva, R., Nazabal, C., Leal, M.J., Martin, A.
System for the expression of heterologous antigens as fusion
proteins. European Patent EP 0 816 506.
[30] Singh, H. and Raghava, G.P. (2001) ProPred: prediction of HLA-
DR binding sites. Bioinformatics 17, 1236–1237.
[31] Swain, M.T., Brooks, A.J., Kemp, G.J.L. (2001) An automated
approach to modelling class II MHC alleles and predicting peptide
binding. In: Proceedings of the Second IEEE International
Symposium on Bio-Informatics and Biomedical Engineering, pp.
81–88. IEEE Computer Society Press.
[32] Parker, K.C., Bednarek, M.A. and Coligan, J.E. (1994) Scheme
for ranking potential HLA-A2 binding peptides based on
independent binding of individual peptide side-chains. J. Immu-
nol. 152, 163–175.
[33] Reche, P.A., Glutting, J.P. and Reinherz, E.L. (2002) Prediction
of MHC class I binding peptides using profile motifs. Hum.
Immunol. 63, 701–709.
[34] Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S.,
Corradin, G. and Lanzavecchia, A. (1989) Universally immuno-
genic T cell epitopes: promiscuous binding to human MHC class
II and promiscuous recognition by T cells. Eur. J. Immunol. 19,
2237–2242.
[35] Babbitt, B.P., Allen, P.M., Matsueda, G., Haber, E. and Unanue,
E.R. (1985) Binding of immunogenic peptides to Ia histocompat-
ibility molecules. Nature 317, 359–361.
[36] Buus, S., Colon, S., Smith, C., Freed, J.H., Miles, C. and Grey,
H.M. (1986) Interaction between a processed ovalbumin peptide
and Ia molecules. Proc. Natl. Acad. Sci. USA 83, 3968–3971.
[37] Guillet, J.G., Lai, M.Z., Briner, T.J., Smith, J.A. and Gefter, M.L.
(1986) Interaction of peptide antigens and class II major
histocompatibility complex antigens. Nature 324, 260–262.
[38] Perez, A., Dickinson, F., Cinza, Z., Ruiz, A., Serrano, T., Sosa, J.,
Gonzalez, S., Gutierrez, Y., Nazabal, C., Gutierrez, O., Guzman,
D., Diaz, M., Delgado, M., Caballero, E., Sardi~nas, G., Alvarez,
A., Martin, A., Guillen, G. and Silva, R. (2001) Safety and
preliminary immunogenicity of the recombinant outer membrane
protein P64k of Neisseria meningitidis in human volunteers.
Biotechnol. Appl. Biochem. 34, 121–125.
